ADC Therapeutics (ADCT) Stock Forecast & Price Target

ADC Therapeutics is favored because Zynlonta is already commercially approved, which lowers regulatory risk while providing tangible cash flows and a proven platform for expansion across additional indications. Its efficacy supports continued physician adoption, and upside could come from deeper penetration and possible success in indolent lymphomas, strengthening the company’s commercial trajectory. Importantly, after the capital raise in 4Q25, ADCT has cash runway until 2028, which appears sufficient to execute the likely opportunity to move into earlier lines of treatment.

ADC Therapeutics is burdened by weak commercial traction, since Zynlonta’s 2Q net sales were only $18.6M and management still sees stable demand in 3L+ DLBCL rather than clear acceleration. The company’s growth case is further undermined by LOTIS-5, where FDA cited “substantial concerns” about benefit-risk, while the trial showed only a modest mPFS gain, no OS benefit, and a higher Grade 5 TEAE rate of 13.2% versus 4.6%. With regulatory risk rising, a limited pipeline, and heavy dependence on one product in the U.S. market, the stock’s fundamentals appear fragile and cash-flow visibility remains poor.